Evotec Overview

  • Founded
  • 1993
Founded
  • Status
  • Public
  • Employees
  • 4,081
Employees
  • Stock Symbol
  • EVT
Stock Symbol
  • Investments
  • 57
  • Share Price
  • $25.95
  • (As of Thursday Closing)

Evotec General Information

Description

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Contact Information

Website
www.evotec.com
Formerly Known As
Evotec BioSystems
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
ETR
Primary Office
  • Manfred Eigen Campus
  • Essener Bogen 7
  • 22419 Hamburg
  • Germany
+49 040 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Evotec Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.95 $25.30 $21.19 - $54.08 $4.48B 177M 513K $1.79

Evotec Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 7,931,474 6,320,026 4,034,746 2,904,384
Revenue 682,886 571,010 499,762 443,003
EBITDA 320,531 101,442 123,801 123,889
Net Income 295,622 7,127 42,620 99,329
Total Assets 2,050,536 1,799,312 1,322,825 882,959
Total Debt 580,661 605,101 518,751 130,937
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Evotec Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Evotec‘s full profile, request access.

Request a free trial

Evotec Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, acade
Drug Discovery
Hamburg, Germany
4,081 As of 2021
00000
000000000 00000

0000000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000 000000000
Cambridge, MA
00 As of 0000
00000
000000000 00000

000 0000

do consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000 000000000
Cambridge, MA
000 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evotec Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genocea Biosciences Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
000 00000000(00000 Corporation Cambridge, MA 000 000.00 00000000 000.00
000000 Formerly VC-backed Little Chesterford, United Kingdom 00 000.00 00000000 000.00
0000000 Formerly PE-Backed Dreieich, Germany 0000 000000&0
00000000 000000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
You’re viewing 5 of 33 competitors. Get the full list »

Evotec Patents

Evotec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180170888-A1 Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases Granted 02-Mar-2015 0000000000
US-10472341-B2 Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases Active 02-Mar-2015 0000000000 0
JP-2018508527-A Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and / or infectious diseases Granted 02-Mar-2015 0000000000
EP-3265463-A1 Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases Granted 02-Mar-2015 0000000000
EP-3265463-B1 Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases Active 02-Mar-2015 C07D285/36
To view Evotec’s complete patent history, request access »

Evotec Executive Team (30)

Name Title Board Seat Contact Info
Werner Lanthaler MD Chief Executive Officer & Executive
Enno Spillner Chief Financial Officer, Finance & Executive
Craig Johnstone Chief Operating Officer, Operations & Executive
Cord Dohrmann Ph.D Chief Scientific Officer & Executive
Hinnerk Rohwedder Senior Specialist Corporate Communications & Executive, Investor Relations
You’re viewing 5 of 30 executive team members. Get the full list »

Evotec Board Members (17)

Name Representing Role Since
00000 000000000 Self Supervisory Board Member 000 0000
000000 00000000 00.0 Carrick Therapeutics Board Member 000 0000
000000 000000 00.0 Evotec Board Member & Vice Chairman 000 0000
0000 000-000000000 00.0 Self Board Member 000 0000
00000 00000 Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Evotec Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evotec Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Evotec‘s full profile, request access.

Request a free trial

Evotec Investments & Acquisitions (57)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 03-May-2022 00000 0000 000.00 Biotechnology 000000 00
00000000 0000 16-Feb-2022 00000 0000 000.00 Drug Discovery 00000 000
000000000 15-Feb-2022 00000 0000 Decision/Risk Analysis 000000 00
000000000 000 18-Aug-2021 00000 0000 0000 Drug Discovery
Topas Therapeutics 02-Jul-2021 Later Stage VC 000.00 Drug Discovery 000000 00
You’re viewing 5 of 57 investments and acquisitions. Get the full list »

Evotec Subsidiaries (3)

Company Name Industry Location Founded
Just Biotherapeutics Biotechnology Seattle, WA 2014
000000 Drug Discovery Princeton, NJ 0000
00000000 Biotechnology Cheshire, United Kingdom 0000
To view Evotec’s complete subsidiaries history, request access »